BAX Baxter International
A broken hospital-supply franchise priced for distress; value hinges entirely on margins recovering to about 13%.
The story
Baxter is a mature, diversified hospital-products company (IV solutions and pumps, injectables, surgical products, Hillrom beds and connected care) that has sold its kidney business to pay down debt after the Hillrom acquisition. It has real scale and an installed-base moat in hospital infusion and IV fluids. Execution problems have repeatedly hurt it: impairments, supply disruptions, and setbacks with the Novum pump have pushed GAAP margins below zero. It is a low-growth turnaround whose value depends on getting margins back to normal for a med-tech company, not on growth.
GAAP margins are depressed by impairments and one-time charges. Adjusted margins have run in the mid-teens, so I assume they recover over 4 years to about 13.5%, roughly where diversified hospital-supply peers settle after amortization. Growth stays close to its 3-4% history. Incremental sales-to-capital of 1.2 is above the 0.74 historical figure because that ratio is inflated by Hillrom goodwill. Beta sits slightly above the 0.9 industry anchor, and failure risk is modest, both reflecting about $7.5B of net debt.
Value drivers
| Revenue growth (Y1) | 3.0% |
| Terminal growth | 2.5% |
| Forecast horizon | 6y |
| Target operating margin | 13.5% |
| Years to target margin | 4 |
| Sales-to-capital | 1.20 |
| Beta | 0.95 |
| Failure probability | 5.0% |
| Cost of capital (WACC) | 7.7% |
| Terminal WACC | 7.9% |
Valuation bridge
| PV of explicit FCFF | 3.03B |
| PV of terminal value | 11.98B |
| Equity value | 7.15B |
| ÷ shares → per share | $13.84 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 11.81B | 3.0% | 2.1% | 198.43M | 286.75M | -88.32M | -81.97M |
| 2 | 12.16B | 2.9% | 5.9% | 568.29M | 285.51M | 282.79M | 243.61M |
| 3 | 12.50B | 2.8% | 9.7% | 958.51M | 283.66M | 674.85M | 539.58M |
| 4 | 12.83B | 2.7% | 13.5% | 1.37B | 281.18M | 1.09B | 807.11M |
| 5 | 13.17B | 2.6% | 13.5% | 1.40B | 278.08M | 1.13B | 775.76M |
| 6 | 13.50B | 2.5% | 13.5% | 1.44B | 274.34M | 1.17B | 744.85M |
Key risks
- Margin recovery stalls because of further pump or quality failures, FDA actions, or new impairments
- Leverage of about $7.5B net debt magnifies any operating miss for equity holders
- Pricing pressure from hospitals and GPOs, plus generic injectables competition, limits growth
Catalysts
- Novum IQ pump relaunch and gains in infusion-system share
- Deleveraging and cost restructuring that lift adjusted margins back above 15%